Advertisement

Lipid Metabolism in Myotonic Dystrophy

  • Hiroto TakadaEmail author
Chapter

Abstract

Lipid metabolism abnormality in myotonic dystrophy (DM) was reviewed. Dyslipidemia is frequently seen in patients with DM. Hypertriglyceridemia, low HDL cholesterolemia, high LDL cholesterolemia, and exceeded visceral fat accumulation are common as abnormal lipid metabolism findings in DM. Dyslipidemia is one of risk factors for metabolic syndrome or nonalcoholic fatty liver disease and is closely relevant to insulin resistance. Careful follow-up for dyslipidemia in DM, especially complicated with glucose intolerance, should be required.

Keywords

Myotonic dystrophy Dyslipidemia Lipid metabolism Insulin resistance Glucose intolerance Metabolic syndrome Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Visceral fat accumulation 

Notes

Acknowledgment

This work was partly supported by grants from the Ministry of Health, Labour and Welfare of Japan (H28-Nanchitou(Nan)-Ippan-030) and Japan Agency for Medical Research and Development (AMED) (17ek0109259).

References

  1. 1.
    Harper PS. Myotonic dystrophy. 3rd ed. London: Sunders WB; 2001.Google Scholar
  2. 2.
    Jenkins S, editor. Myotonic dystrophies. Epidemiology, diagnosis and therapeutic challenges. New York: Nova Biomedical; 2015.Google Scholar
  3. 3.
    Takada H, Kon S, Oyama Y, Goto T. Oral fat loading study: does specific hyperlipemia exist in myotonic dystrophy type 1? Neuromuscul Disord. 2010;20(9–10):627.CrossRefGoogle Scholar
  4. 4.
    Hudson AJ, Huff MW, Wright CG, Silver MM, Lo TCY, Banerjee D. The role of insulin resistance in the pathogenesis of myotonic muscular dystrophy. Brain. 1987;110(2):469–88.CrossRefGoogle Scholar
  5. 5.
    Moorjani S, Gaudet D, Laberge C, Thibault MC, Mathieu J, Morissette J, Lupien PJ, Brun D, Gagné C. Hypertriglyceridemia and lower LDL cholesterol concentration in relation to apolipoprotein E phenotypes in myotonic dystrophy. Can J Neurol Sci. 1989;16(1):129–33.CrossRefGoogle Scholar
  6. 6.
    Rakocevic Stojanovic V, Peric S, Lavrnic D, Popovic S, Ille T, Stevic Z, Basta I, Apostolski S. Leptin and the metabolic syndrome in patients with myotonic dystrophy type 1. Acta Neurol Scand. 2010;121(2):94–8.CrossRefGoogle Scholar
  7. 7.
    Daniele A, De Rosa A, De Cristofaro M, Monaco ML, Masullo M, Porcile C, Capasso M, Tedeschi G, Oriani G, Di Costanzo A. Decreased concentration of adiponectin together with a selective reduction of its high molecular weight oligomers is involved in metabolic complications of myotonic dystrophy type 1. Eur J Endocrinol. 2011;165(6):969–75.CrossRefGoogle Scholar
  8. 8.
    Vujnic M, Peric S, Popovic S, Raseta N, Ralic V, Dobricic V, Novakovic I, Rakocevic-Stojanovic V. Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve. 2015;52(2):273–7.CrossRefGoogle Scholar
  9. 9.
    Takada H, Kon S, Oyama Y, Kimura T, Nagahata F. The number of CTG repeat is correlated with the accumulation of visceral fat in myotonic dystrophy type 1. Eur J Neurol. 2016;23(Suppl 1):692.Google Scholar
  10. 10.
    Takada H, Kon S, Oyama S, Kimura T. Liver functional impairment in myotonic dystrophy type 1. Neuromuscul Disord. 2016;26(Suppl 2):195.CrossRefGoogle Scholar
  11. 11.
    Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007;8(1):21–34.CrossRefGoogle Scholar
  12. 12.
    Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26(8):2442–50.CrossRefGoogle Scholar
  13. 13.
    Fernández-Real JM, Molina A, Broch M, Ricart W, Gutiérrez C, Casamitjana R, Vendrell J, Soler J, Gómez-Sáez JM. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy. Diabetes. 1999;48(5):1108–12.CrossRefGoogle Scholar
  14. 14.
    Prasad P, Kochhar A. Interplay of vitamin D and metabolic syndrome: a review. Diabetes Metab Syndr. 2016;10(2):105–12.CrossRefGoogle Scholar
  15. 15.
    Terracciano C, Rastelli E, Morello M, Celi M, Bucci E, Antonini G, Porzio O, Tarantino U, Zenobi R, Massa R. Vitamin D deficiency in myotonic dystrophy type 1. J Neurol. 2013;260(9):2330–4.CrossRefGoogle Scholar
  16. 16.
    Passeri E, Bugiardini E, Sansone VA, Valaperta R, Costa E, Ambrosi B, Meola G, Corbetta S. Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies. J Neurol Sci. 2013;331(1–2):132–5.CrossRefGoogle Scholar
  17. 17.
    Lovadi E, Csereklyei M, Merkli H, FüLöp K, Sebők Á, Karcagi V, Komoly S, Pál E. Elevated FGF 21 in myotonic dystrophy type 1 and mitochondrial diseases. Muscle Nerve. 2017;55(4):564–9.CrossRefGoogle Scholar
  18. 18.
    Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, Schneider C, Koch MC, Beilman GJ, Harrison AR, Dalton JC, Ranum LP. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60(4):657–64.CrossRefGoogle Scholar
  19. 19.
    Screen M, Jonson PH, Raheem O, Palmio J, Laaksonen R, Lehtimäki T, Sirito M, Krahe R, Hackman P, Udd B. Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions. Am J Pathol. 2014;184(8):2322–32.CrossRefGoogle Scholar
  20. 20.
    Nozaki S, Miyai I, Kang J. Intra-abdominal visceral fat in myotonic dystrophy. Rinsho Shinkeigaku. 1992;32(5):521–3.PubMedGoogle Scholar
  21. 21.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefGoogle Scholar
  22. 22.
    Pu J, Romanelli R, Zhao B, Azar KM, Hastings KG, Nimbal V, Fortmann SP, Palaniappan LP. Dyslipidemia in special ethnic populations. Cardiol Clin. 2015;33(2):325–33.CrossRefGoogle Scholar
  23. 23.
    Achiron A, Barak Y, Magal N, Shohat M, Cohen M, Barar R, Gadoth N. Abnormal liver test results in myotonic dystrophy. J Clin Gastroenterol. 1998;26(4):292–5.CrossRefGoogle Scholar
  24. 24.
    Shieh K, Gilchrist JM, Promrat K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle Nerve. 2010;41(2):197–201.PubMedGoogle Scholar
  25. 25.
    Bhardwaj RR, Duchini A. Non-alcoholic steatohepatitis in myotonic dystrophy: DMPK gene mutation, insulin resistance and development of steatohepatitis. Case Rep Gastroenterol. 2010;4(1):100–3.CrossRefGoogle Scholar
  26. 26.
    Ariake K, Miura M, Takahashi M, Ueno T, Sato S, Akada M, Maeda S, Fujisaka Y, Ohto T, Naito H. A case of liver cirrhosis due to non-alcoholic steatohepatitis complicated by myotonic dystrophy. Nihon Shokakibyo Gakkai Zasshi. 2013;110(9):1633–9.PubMedGoogle Scholar
  27. 27.
    Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.CrossRefGoogle Scholar
  28. 28.
    Sando KR, Knight M. Nonstatin therapies for management of dyslipidemia: a review. Clin Ther. 2015;37(10):2153–79.CrossRefGoogle Scholar
  29. 29.
    Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163(5):553–6.CrossRefGoogle Scholar
  30. 30.
    Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6.CrossRefGoogle Scholar
  31. 31.
    Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P, ASCOT. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.National Hospital Organization Aomori National HospitalAomoriJapan

Personalised recommendations